Floatz logo

Everolimus

Inoperable

Amsterdam UMC, location VUmcSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Inoperable cohort.

Asset / SponsorPhaseRating
Lapatinib
Amsterdam UMC, location VUmc
N/AD
Sorafenib
Amsterdam UMC, location VUmc
N/AD
Dasatinib
Amsterdam UMC, location VUmc
N/AD
su011248
Amsterdam UMC, location VUmc
N/AD

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →